The core idea behind CALT-GNN, which stands for Cross-Attention and Long-Tail Expert Graph Neural Network, is to represent patients not as isolated rows of numbers but as nodes in a network. The method begins by constructing separate patient-similarity graphs for each omics layer, meaning that patients are linked to one another when their copy number alteration profiles, DNA methylation patterns, or messenger RNA expression signatures resemble each other. Graph convolutional networks then learn latent representations of each patient within these graphs, allowing information to flow between molecularly similar individuals. Finally, a technique known as similarity network fusion merges the separate graphs into a single unified network that captures relationships spanning all the molecular layers at once.

This graph-based strategy addresses the first major challenge in multi-omics cancer classification: high dimensionality. Each patient in a typical multi-omics dataset carries tens of thousands of molecular measurements, spanning genomic, epigenomic, transcriptomic, and sometimes proteomic levels. Feeding such high-dimensional vectors directly into a classifier invites overfitting and obscures the biological relationships between data types. By converting patients into nodes embedded in similarity graphs, the framework reduces the effective complexity of the problem and lets the learning algorithm exploit the structure of the data, namely the fact that patients with similar molecular profiles tend to belong to the same subtype.

The second innovation lies in how the model integrates different omics types with one another. Rather than simply concatenating measurements from copy number alteration, DNA methylation, and mRNA expression into one long vector, CALT-GNN employs a cross-attention branch that explicitly models the complementary relationships between modalities. In this design, copy number alteration and DNA methylation serve as source modalities, while mRNA expression acts as the target modality. Cross-attention, a mechanism borrowed from modern deep learning architectures, allows the model to learn which features in the source modalities are most informative for interpreting each feature in the target modality. Biologically, this mirrors real regulatory logic: DNA copy number changes and methylation patterns both influence gene expression, and the model can, in principle, learn those influences directly from the data.

The third component tackles the long-tail problem, which is arguably the most underappreciated obstacle in cancer subtype classification. Real cancer cohorts are almost never balanced. A common subtype may account for the majority of patients in a dataset, while rare but clinically important subtypes may be represented by only a handful of samples. Standard classifiers, optimized for overall accuracy, tend to become experts on the common subtypes and largely ignore the rare ones, which is precisely backwards from a clinical standpoint, since correctly identifying a rare subtype may be the most consequential decision for an individual patient. CALT-GNN addresses this with a long-tail expert branch built around two specialized components: a Major Expert and a Minor Expert, combined with prototype-guided routing that directs each sample toward the expert best suited to its position in the class distribution.

The routing mechanism works by comparing a patient’s learned representation against class prototypes, essentially reference points that summarize what each subtype looks like in the model’s internal feature space. Samples that resemble well-populated classes are handled by the Major Expert, which is tuned to the dense regions of the data, while samples from sparse, rare subtypes are routed to the Minor Expert, which specializes in the long tail of the distribution. This class-distribution-aware strategy means the model does not force a single classifier to serve both the abundant and the scarce subtypes simultaneously, a compromise that typically degrades performance on the rare end of the spectrum.

To combine the insights from the cross-attention branch and the long-tail expert branch, the framework uses a learnable global weight that determines how much each branch contributes to the final prediction. Rather than fixing this balance in advance, the model learns it during training, allowing the optimal mixture to differ across cancer types and datasets. The authors report that ablation studies, in which individual components were removed to test their contribution, supported the complementary roles of cross-omics interaction modeling and adaptive long-tail expert routing, although the magnitude of the improvements varied across cohorts and subtypes, a candid acknowledgment that no single mechanism dominates in every setting.

The evaluation was conducted on eight multi-omics cohorts drawn from The Cancer Genome Atlas, one of the largest and most widely used public resources in cancer genomics. The datasets were obtained in processed form from the MO-GCAN repository on Figshare, which derives from TCGA PanCancer Atlas data accessed through cBioPortal. Because the data are publicly available and de-identified, the study required no additional ethics approval. Across the eight cohorts, CALT-GNN achieved competitive or comparable classification performance relative to representative baseline methods, with particularly stable results on two metrics that are sensitive to class imbalance: Macro-F1, which averages the F1 score across classes so that rare subtypes count as much as common ones, and the Matthews Correlation Coefficient, which provides a balanced measure of classification quality even when class sizes differ sharply.

The choice of these two metrics is significant. A model can post an impressive overall accuracy simply by predicting the most common subtype for nearly every patient, while failing almost completely on rare ones. Macro-F1 and MCC expose such failures, and CALT-GNN’s stability on these measures suggests that its long-tail machinery is doing real work rather than merely inflating headline numbers. The authors also performed subtype-level analyses to examine how the model behaved on individual classes, providing a more granular picture than aggregate scores alone. For a field where the clinically hardest cases are often the rarest, this emphasis on imbalance-sensitive evaluation is a methodological point worth emphasizing.

None of this means that CALT-GNN is ready to guide treatment decisions in a clinic tomorrow. The study is a methodological contribution, demonstrating a framework and benchmarking it against existing approaches on public data, and the authors themselves note that improvements varied in magnitude across cohorts and subtypes. But the work illustrates a broader and important trend in computational oncology: the recognition that the hardest problems in cancer subtyping are not just about bigger models or more data, but about the structure of the data itself, including the tangled regulatory relationships among genomic layers and the skewed distributions of disease subtypes. By building those two realities directly into the architecture of a graph neural network, the Hunan City University team has offered a template that other researchers working on multi-omics integration, from rare disease classification to drug response prediction, may well find worth adapting. The paper is open access, and the underlying data are publicly available, lowering the barrier for the community to test, refine, and extend the approach.

Subject of Research: A graph neural network framework for multi-omics cancer subtype classification addressing cross-omics relationships and imbalanced subtype distributions

Article Title: CALT-GNN: a graph neural network with cross-attention and long-tail experts for multi-omics cancer subtype classification

Article References: Wang, K., Zheng, J., Zhao, L., Xiao, W., Li, Z., & He, Q. (2026). CALT-GNN: a graph neural network with cross-attention and long-tail experts for multi-omics cancer subtype classification. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06683-x

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06683-x

Keywords: multi-omics integration, cancer subtype classification, graph neural network, cross-attention, long-tail learning, TCGA, copy number alteration, DNA methylation, mRNA expression, class imbalance, precision oncology, bioinformatics

To understand why the new model matters, it helps to revisit what RNA velocity actually measures. Standard single-cell RNA sequencing counts mature, spliced transcripts, but many protocols also capture unspliced nascent RNA that has not yet been processed. Because unspliced RNA reflects genes that a cell has recently started transcribing, the ratio between unspliced and spliced counts for each gene provides a hint about whether that gene is being induced or repressed. By combining these signals across thousands of genes, RNA velocity methods can infer a vector field over the cell population, pointing each cell toward its likely future state. This allows researchers to reconstruct developmental trajectories, identify lineage relationships, and predict the endpoints of differentiation without needing time-series measurements.

The original formulation of RNA velocity relied on a dynamical model of splicing kinetics, treating the interplay between unspliced and spliced RNA as a set of ordinary differential equations whose parameters could be estimated from the data. While elegant, this approach struggles with the noise, dropout, and sparsity that plague single-cell datasets, and it often produces inconsistent velocity estimates across complex, multi-lineage systems. Subsequent methods have taken different routes: some simplify the problem by assuming steady-state kinetics, while others turn to neural networks to learn the velocity field directly from latent representations of gene expression. These neural approaches have improved robustness, but they come with their own limitations, particularly in how they model relationships between cells.

A key weakness of many current neural velocity models, the authors of the new study argue, lies in their reliance on local neighborhood structure. Most pipelines begin by constructing a k-nearest neighbor graph in a reduced-dimensional space, typically using principal component analysis to compress the high-dimensional expression profiles. The graph is meant to approximate the local geometry of the transcriptional manifold, and velocity information is propagated only between neighboring cells. Yet in real tissues, biologically related cells may not be nearest neighbors in the embedding space. Cells that lie far apart in the graph can still share developmental ancestry or be destined for similar fates, and these long-range dependencies carry information that a purely local model discards. Capturing them requires an architecture capable of attending to arbitrary pairs of cells rather than only to immediate neighbors.

That is precisely where the transformer comes in. Transformers, the architecture family that underpins modern large language models, are built around self-attention, a mechanism that lets each element in a set compute weighted relationships with every other element. Multi-head attention extends this by running several attention computations in parallel, each with its own learned projection, so that different heads can specialize in different kinds of relationships. Applied to single-cell data, a graph transformer can in principle learn which cells are relevant to one another regardless of their distance in the neighborhood graph, while the graph structure itself provides an inductive bias that keeps the model grounded in the observed topology of the data. GTVelo combines these ingredients within a neural ordinary differential equation framework, meaning that the learned attention-based representation feeds into a continuous-time dynamical model of how cell states evolve.

The neural ordinary differential equation component is significant in its own right. Rather than discretizing time into steps, a neural ODE defines the derivative of the cell’s latent state as the output of a neural network, and the trajectory is obtained by integrating that derivative forward. This continuous formulation is a natural fit for RNA velocity, which is fundamentally about the instantaneous rate of change of transcriptional state. It also allows the model to produce smooth trajectories through latent space, which is important when the underlying biology involves gradual differentiation rather than abrupt jumps between discrete states. By embedding the transformer-based encoder inside this dynamical system, GTVelo seeks to couple rich relational modeling of the cell population with principled temporal dynamics.

One of the more distinctive features of the new model is what the authors call a multi-origin state mechanism. Many existing approaches effectively assume that all trajectories in a dataset can be described starting from a single initial state, which becomes problematic in datasets containing multiple lineages, branching differentiation paths, or heterogeneous cell populations. A single origin forces the model to squeeze fundamentally different developmental stories into one shared starting point, degrading the accuracy of velocity estimates for every lineage involved. GTVelo instead allows inference to proceed from multiple origins, which the authors say enables flexible handling of multi-branch trajectories. This flexibility also extends to data integration: the model is designed to accommodate multi-omics inputs, reflecting the growing trend in genomics toward assays that measure RNA alongside chromatin accessibility, protein abundance, or other molecular layers in the same cells.

According to the study, GTVelo was evaluated across multiple benchmark datasets and compared against established RNA velocity methods using standard evaluation metrics. The reported results show competitive performance overall, with GTVelo outperforming the compared methods on most of the standard metrics in most cases. Two of the evaluation concepts highlighted in the paper are cross-boundary directedness, which measures whether inferred velocities correctly point across the boundaries between clusters in a biologically consistent direction, and in-cluster coherence, which assesses whether velocity vectors within a cluster are mutually consistent rather than pointing in conflicting directions. Together, these metrics probe whether a velocity model captures both the global organization of a trajectory and the local smoothness of the inferred dynamics, two properties that are often in tension.

The implications for downstream biology could be substantial. RNA velocity is widely used to annotate developmental hierarchies, trace the origins of disease-associated cell states, and generate hypotheses about lineage commitment in contexts ranging from embryogenesis to tumor evolution. Models that handle branching trajectories and long-range cellular associations more reliably could improve the fidelity of these analyses, particularly in complex tissues where multiple lineages coexist and where rare transitional populations carry outsized biological importance. The stated ability to integrate multi-omics data points toward applications in which velocity is estimated from joint measurements, potentially revealing regulatory dynamics that transcript-only models cannot see. As with any computational method, real-world performance will depend on how the benchmarks translate to noisy, dataset-specific conditions, and independent validation by the community will be an important next step.

The research was carried out by Shensi Huang, Hongyu Zhang, and Jianping Zhao of Xinjiang University, together with Zile Wang of Dalian University of Technology, Haiyun Wang of Wuhan University of Science and Technology, and Junfeng Xia of Anhui University, and was supported by funding including grants from the National Natural Science Foundation of China. The article was published open access in BMC Bioinformatics on 15 September 2026, with the accepted manuscript shared early under a permanent DOI. For a field that has seen a rapid succession of velocity methods, each claiming incremental gains, GTVelo’s contribution lies in bringing the attention machinery of modern deep learning to bear on a problem that has long been constrained by local graph assumptions and single-origin trajectory models. Whether graph transformers become a standard component of the single-cell dynamics toolbox, the study adds a technically grounded option for researchers wrestling with the messy, branching reality of cellular differentiation.

Subject of Research: RNA velocity inference in single-cell transcriptomics using a graph transformer-based neural ordinary differential equation model

Article Title: RNA velocity inference based on graph transformer

Article References: Huang, S., Wang, Z., Zhang, H., Wang, H., Zhao, J., & Xia, J. (2026). RNA velocity inference based on graph transformer. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06550-9

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06550-9

Keywords: RNA velocity, single-cell RNA sequencing, graph transformer, neural ordinary differential equations, trajectory inference, cell differentiation, deep learning, multi-head attention, multi-omics integration, transcriptomics, computational biology, BMC Bioinformatics

The core insight behind DePass is deceptively simple: instead of treating noise removal and data integration as two separate problems to be solved in sequence, the framework couples them into a single iterative loop. Raw omics data are first organized into graphs, mathematical structures in which each cell or spatial spot is a node and edges connect measurements that are likely to be biologically related. The system then performs neighbourhood aggregation, borrowing information from connected nodes to smooth out spurious fluctuations in each modality. Crucially, the denoised data feed into an integration module that produces a unified embedding, a compact mathematical representation of each cell that fuses information across all measured layers. That embedding, in turn, is used to refine the enhancement step, and the cycle repeats. Each pass through the loop sharpens both the cleaned data and the integrated result, which is why the authors describe their architecture as dual-enhanced.

This coupled design addresses a weakness that has plagued earlier integration methods. Most existing tools were built with the assumption that the input data are reasonably clean, and they focus their mathematical machinery on aligning modalities that measure different aspects of biology. Yet multimodal experiments are inherently noisier than single-modality profiling, because each additional measurement layer introduces its own sources of dropout, batch effects and stochastic variation. When a framework ignores this elevated noise, the errors propagate into the integrated embedding, blurring the very biological distinctions the analysis is meant to reveal. By iteratively denoising while integrating, DePass prevents that degradation and, according to the authors’ benchmarks, recovers sharper and more faithful cellular structure.

The second major innovation is scope. Many current integration methods are tailored to a specific data type: some excel at single-cell experiments, where each cell carries paired measurements across modalities, while others are designed for spatial platforms, where molecular readouts are mapped onto tissue coordinates. DePass was engineered from the ground up to handle both contexts within a single framework. Whether the input is a single-cell multi-omics dataset, a spatial transcriptomics and proteomics experiment, or a spatial epigenomic profile, the same graph learning architecture applies. This generality matters for a field that is expanding explosively, with new experimental platforms appearing every year and laboratories increasingly unwilling to learn a different computational tool for each one.

To substantiate claims of generality, the team mounted an unusually comprehensive benchmarking campaign. DePass was evaluated across six modalities, nine tissue types and thirteen experimental platforms, spanning datasets from mouse brain and spleen to human tonsil, mouse embryo and human tumour tissue. The platforms ranged from established commercial systems such as 10x Genomics multiome assays to cutting-edge methods including Spatial-mux-seq, which captures four modalities simultaneously in mouse embryo tissue, and MISAR-seq, which jointly profiles gene expression and chromatin accessibility in spatial context. Across this gauntlet of tests, DePass demonstrated superior integration accuracy compared with competing methods, measured by quantitative metrics of how well cells cluster by biological identity rather than technical artifact.

Among the most striking demonstrations is the framework’s handling of spatial metabolomics. The researchers applied DePass to a mouse brain dataset combining Visium spatial transcriptomics with MALDI mass spectrometry imaging, a pairing that captures both the transcriptomic and metabolic state of tissue in register. Metabolomic data are notoriously noisy and sparse, making them a stern test of any denoising approach. DePass not only integrated the two layers coherently but also strengthened the correlations between genes and metabolites, sharpening anatomical boundaries in the enhanced data compared with the raw measurements. Similar gains appeared in a mouse spleen spatial transcriptomics and proteomics dataset, where enhancement improved the spatial coherence of marker gene and protein expression patterns.

The framework also proved its worth on clinical material. The team generated an in-house colorectal cancer dataset using Stereo-CITE-seq, a technology that profiles gene expression and surface proteins across intact tumour tissue at high resolution. When DePass was applied to this data, it uncovered substructure within immune niches that had been invisible in less carefully integrated analyses, and it resolved spatial heterogeneity within the tumour at near single-cell resolution. For cancer researchers, this kind of resolution is not a luxury. Tumours are mosaics of malignant cells, immune infiltrates, fibroblasts and vasculature, and the arrangement of these components shapes how the disease progresses and how patients respond to therapy. A tool that can faithfully integrate transcriptomic and proteomic views of that architecture could sharpen the identification of biomarkers and therapeutic targets.

Further applications underscored the breadth of the method. In hepatocellular carcinoma data combining Xenium transcriptomics with CODEX protein imaging, DePass detected a rare population of cDC1 dendritic cells, a cell type of intense interest in cancer immunology because of its role in priming antitumour immune responses, even though it comprised less than 0.15 percent of all cells. In a mouse embryo Spatial-mux-seq dataset spanning four modalities, the framework wove together transcriptomic, epigenomic and protein-level information into a coherent developmental picture. And on single-cell tri-modality datasets such as TEA-seq and DOGMA-seq, which measure transcripts, epitopes and chromatin accessibility simultaneously in individual cells, DePass preserved biologically meaningful dynamics, including cell-cycle progression reconstructed through pseudotime analysis.

Practical considerations may prove as important as raw performance. The authors report that DePass is scalable, employing efficient graph construction and training strategies that keep computational demands manageable even for large datasets, and they provide running time evaluations across their benchmark collection. The software is open source, with code deposited on GitHub and Zenodo, full documentation, and a detailed protocol published through protocols.io. Processed data from the study are publicly available through Zenodo and the China National Center for Bioinformation, and the paper’s data availability section catalogues accession numbers for every dataset analysed. This transparency lowers the barrier for other laboratories to adopt, test and extend the framework, which is often what determines whether a new method becomes a community standard or a footnote.

The arrival of DePass reflects a broader maturation of computational biology. A decade ago, the bottleneck in genomics was generating data; today, it is making sense of data whose complexity has outpaced the tools designed to analyse them. Multi-omics experiments hold the promise of capturing biology in its full dimensionality, but only if the layers can be fused without injecting artifacts. By building denoising into the integration process itself and by refusing to specialize in a single data type, DePass offers a template for what next-generation analysis frameworks may look like: unified, generalizable and honest about the noise inherent in real measurements. If the benchmarks hold up under independent scrutiny, the framework could become a standard workhorse in laboratories charting the molecular geography of tissues, from developing embryos to tumours on the operating table.

Subject of Research: A graph-based deep learning framework for integrating paired single-cell and spatial multi-omics data

Article Title: The dual-enhanced graph learning framework DePass allows paired data integration in single-cell and spatial multiomics

Article References: Li, W., Jiang, Y., Zhao, Q., Xu, Y., Dai, D., Rong, Y., Zhao, X., & Zhang, H. (2026). The dual-enhanced graph learning framework DePass allows paired data integration in single-cell and spatial multiomics. Nature Cell Biology. https://doi.org/10.1038/s41556-026-02067-8

Image Credits: AI Generated

DOI: 10.1038/s41556-026-02067-8

Keywords: DePass, multi-omics integration, single-cell sequencing, spatial transcriptomics, graph neural networks, deep learning, denoising, colorectal cancer, tumour microenvironment, spatial proteomics, computational biology, Nature Cell Biology

The research team enrolled 342 consecutive patients with advanced lung cancer who were receiving immunotherapy, randomly assigning them to training and validation sets. From each patient, the investigators collected baseline measurements spanning three complementary domains: standard clinical parameters, systemic inflammatory markers, and multi-omics features that capture the biological state of the tumor and its surrounding immune environment. The logic behind this breadth is straightforward. Response to checkpoint inhibitors is not governed by a single molecule but by an intricate interplay between tumor genetics, immune cell infiltration, and the overall physiological condition of the patient. By pooling variables from each of these layers, the researchers aimed to build a predictor that reflects the full biological complexity of the disease.

The first analytical step was to identify which of the many collected variables actually separated responders from non-responders. Univariate analysis flagged six factors with statistically significant differences between the two groups, all at P values below 0.05: tumor mutational burden, known as TMB; a composite TIME score reflecting the tumor immune microenvironment; the neutrophil-to-lymphocyte ratio, or NLR; the platelet-to-lymphocyte ratio, or PLR; serum lactate dehydrogenase, or LDH; and albumin. Multivariate logistic regression then confirmed that all six remained independent predictors when their effects were adjusted against one another, a crucial check ensuring that none of the associations was merely an artifact of correlation with another variable.

Each of these six predictors tells a distinct biological story. Tumor mutational burden measures the number of mutations carried by the tumor, and a higher burden generally means the cancer cells produce more abnormal proteins that the immune system can recognize as foreign, making checkpoint blockade more likely to unleash an effective attack. The TIME score, by contrast, probes the local battlefield within and around the tumor, characterizing the density and composition of immune cells in the microenvironment. The NLR and PLR capture systemic inflammation from a routine blood count; elevated ratios often signal a pro-tumor inflammatory state in which neutrophils and platelets suppress the antitumor activity of lymphocytes. LDH is a marker of tumor burden and tissue breakdown, frequently elevated in aggressive disease, while low albumin reflects poor nutritional status and systemic illness, both of which can blunt the immune response that immunotherapy depends on.

With six independent predictors in hand, the team constructed three machine learning models to integrate them: random forest, support vector machine, and logistic regression. Each approach handles the data differently. Logistic regression fits a linear relationship between the predictors and the probability of response, offering transparency but limited flexibility. A support vector machine finds the boundary that best separates responders from non-responders in a high-dimensional feature space, while a random forest builds hundreds of decision trees on random subsets of the data and averages their votes, a strategy that captures nonlinear interactions and is inherently resistant to overfitting when properly tuned.

The random forest emerged as the clear winner. In the training set it achieved an area under the receiver operating characteristic curve, or AUC, of 0.835 with a 95 percent confidence interval of 0.776 to 0.895, and in the validation set it delivered a nearly identical AUC of 0.832 with a confidence interval of 0.740 to 0.925. That consistency between cohorts is the strongest evidence that the model has learned genuine biological signal rather than statistical noise. Logistic regression performed respectably, with AUCs of 0.822 in training but a drop to 0.757 in validation, while the support vector machine lagged behind at 0.773 and 0.749 respectively. The tight confidence intervals and the minimal degradation from training to validation together suggest a robust and generalizable tool.

Performance metrics alone, however, do not tell clinicians why a model makes a particular prediction, and black-box medicine has rightly drawn skepticism. To open the box, the researchers applied SHAP analysis, a technique derived from cooperative game theory that quantifies each feature’s contribution to individual predictions. The SHAP ranking placed the neutrophil-to-lymphocyte ratio first, followed by the TIME score, the platelet-to-lymphocyte ratio, tumor mutational burden, LDH, and albumin. This ordering is provocative. It suggests that systemic inflammatory markers, easily obtained from a simple blood draw, carry at least as much predictive weight as tumor mutational burden, which requires expensive genomic sequencing. If confirmed in larger studies, that finding could make sophisticated response prediction far more accessible in settings where advanced molecular diagnostics are unavailable.

Beyond discrimination, the team evaluated calibration and clinical utility. Calibration curves showed good agreement between predicted probabilities and observed outcomes, meaning that when the model says a patient has, for example, a 70 percent chance of responding, roughly 70 percent of such patients actually do. Decision curve analysis, which compares the net benefit of acting on the model’s predictions against default strategies such as treating everyone or treating no one, confirmed high clinical net benefit across a broad range of threshold probabilities. These are the tests that separate a scientifically interesting classifier from one that can safely inform real treatment decisions, and the model passed both.

The practical implications are considerable. Patients with advanced lung cancer typically face a choice between immunotherapy, chemotherapy, combinations, or other targeted approaches, and each option carries costs, toxicities and opportunity costs. A patient predicted to respond strongly could proceed to immunotherapy with confidence, while a patient predicted to be resistant might be steered toward alternatives or into combination trials designed to overcome primary resistance. The authors position their model as an objective, quantitative decision-support tool for individualized immunotherapy management, a supplement to clinical judgment rather than a replacement for it.

Caveats remain. The study was conducted at a single institution in China, and validation in independent, multiethnic cohorts will be needed before widespread adoption. The TIME score, while powerful, requires specialized assessment of tumor samples that not all centers can provide routinely. And as an early-access, peer-reviewed publication, the article may undergo minor editorial revisions before the final version of record. Even so, the study exemplifies a growing trend in oncology: rather than searching for one perfect biomarker, researchers are integrating many modest signals across biological scales with machine learning to produce predictions that outperform any single measure. For a disease that kills more people worldwide than any other cancer, a validated tool that helps put each patient on the right therapy the first time is a development worth watching closely.

Subject of Research: A multiomics machine learning model for predicting immunotherapy response in advanced lung cancer

Article Title: A multiomics model for predicting immunotherapy response in advanced lung cancer

Article References: A multiomics model for predicting immunotherapy response in advanced lung cancer. (n.d.). https://doi.org/10.1007/s00432-026-06603-9

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06603-9

Keywords: advanced lung cancer, immunotherapy, multi-omics integration, machine learning, random forest, tumor mutational burden, neutrophil-to-lymphocyte ratio, tumor immune microenvironment, SHAP analysis, predictive model, biomarkers, cancer immunotherapy

The framework, called HCAM-BRCA, short for Hierarchical Cross-Attention Multi-omics, tackles a problem that has dogged computational oncology for years: how to combine different kinds of molecular data without losing the biological relationships between them. Modern cancer research generates information from multiple molecular layers simultaneously. Messenger RNA profiles reveal which genes are being actively transcribed into protein-building instructions. MicroRNA profiles capture short regulatory molecules that silence gene expression after transcription. DNA methylation data, measured at cytosine-phosphate-guanine sites across the genome, show chemical tags that can switch genes on or off without altering the underlying sequence. Each layer tells part of the story, and each layer regulates the others in a web of interactions that single-omics analyses simply cannot see.

Many existing integration approaches handle this complexity in limited ways. Some methods analyze one data type at a time, while others combine only two layers in pairwise fashion, for instance joining RNA and microRNA data or RNA and methylation data but never all three at once. More importantly, most approaches do not explicitly model the hierarchical regulatory structure that connects the layers: methylation influences transcription, microRNAs modulate messenger RNA, and feedback loops run in both directions. HCAM-BRCA was designed to capture exactly these relationships. The architecture applies modality-specific self-attention to each data type, allowing the model to learn which features within a layer depend on one another, and then deploys cross-attention mechanisms between layers so the model can learn how, for example, methylation patterns inform the interpretation of gene expression.

Attention mechanisms are the same mathematical machinery that powers modern large language models, and their great advantage here is interpretability. Rather than acting as an inscrutable black box, an attention-based model assigns weights that reveal which features it considered most important when making a decision. In HCAM-BRCA, those weights translate directly into a ranked list of genes and regulatory elements that drove each subtype classification. The learned low-dimensional embeddings, compact numerical representations of each tumor’s multi-omics profile, were then fed into a battery of conventional machine learning classifiers, allowing the researchers to test how well the attention-derived representation supported downstream prediction.

The results were evaluated on data from The Cancer Genome Atlas, the large public repository of de-identified tumor profiles that has become the workhorse of computational cancer research. Performance was measured with rigorous statistics, including the Matthews correlation coefficient, a demanding metric that accounts for class imbalance, and the area under the precision-recall curve, which is particularly informative when one subtype is rare. All metrics were reported as means with standard deviations across five-fold cross-validation, meaning the data were repeatedly split so that every model was tested on samples it had never seen during training. The researchers also addressed a common pitfall in cancer genomics: class imbalance, where some subtypes have far fewer samples than others. Using an adaptive synthetic sampling technique known as ADASYN, they generated balanced training sets to prevent the models from simply defaulting to the most common categories.

Across every classifier tested, HCAM-BRCA’s three-layer integration outperformed the pairwise RNA-microRNA and RNA-CpG strategies, confirming that the full hierarchical picture carries information that two-layer views miss. Among the twelve machine learning models evaluated, CatBoost, a gradient-boosting method, achieved the highest macro-average Matthews correlation coefficient at 0.7628 with a standard deviation of 0.0130, while Extra Trees attained the highest area under the precision-recall curve at 0.8925 with a standard deviation of 0.0032. Those numbers represent strong and stable discrimination across subtypes, and notably the framework performed well precisely where existing tools struggle most, in separating the clinically challenging Luminal B and Her2-enriched categories.

Accuracy alone, however, was only half the story. Because the model’s attention weights expose which features influenced each decision, the researchers could interrogate the biology behind the predictions. Attention-based feature prioritization surfaced genes associated with transcriptional regulation, chromatin organization, immune signaling, and established cancer-related pathways, a pattern consistent with what independent functional analyses using Gene Ontology and KEGG pathway annotations would expect from genuinely relevant candidates. In other words, the model was not latching onto statistical noise; it was converging on genes that biologists already recognize as players in tumor behavior, along with others that merit new investigation.

The most clinically provocative findings came from survival analysis. The team examined whether expression of the prioritized genes was associated with patient outcomes within specific subtypes, and several strong subtype-specific prognostic links emerged. In Basal-like tumors, the aggressive category that largely overlaps with triple-negative breast cancer, the genes CUX1, MYZAP, and CEBPA showed significant survival associations. In Luminal B tumors, HOXA10, a developmental regulator frequently implicated in cancer, and HLA-DQA2, an immune-related gene, carried prognostic weight. In Her2-enriched tumors, GDF10 and ZNF879 were associated with survival outcomes. Each of these associations suggests a potential biomarker that could, with further validation, help stratify patients within a subtype for more tailored follow-up or therapy.

The significance of such subtype-specific markers is easy to underestimate. A gene that predicts poor survival in Basal-like tumors may be irrelevant in Luminal B, and pooling all subtypes together in a single analysis can wash out these signals entirely. By classifying first and then probing survival within each molecular category, HCAM-BRCA mirrors the way precision oncology actually operates: treatment decisions are made for a specific patient with a specific tumor subtype, not for an average cancer. A framework that simultaneously classifies accurately and nominates candidate biomarkers within each class therefore addresses two bottlenecks in the same pipeline.

The study, published open access on 23 September 2026 with no external funding, arrives amid a broader wave of multi-omics integration methods, including graph convolutional approaches such as MOGONET and neural frameworks like moBRCA-net. What distinguishes HCAM-BRCA is its explicit attention to hierarchical cross-layer regulation and the interpretability that attention weights provide. The authors acknowledge that the work rests on publicly available TCGA data and used no new human subjects, which means the biomarker candidates remain hypotheses awaiting validation in independent cohorts and, eventually, clinical settings. Still, the combination of robust subtype classification, biologically coherent feature prioritization, and subtype-specific prognostic signals makes a compelling case that teaching artificial intelligence to read all three molecular layers of a tumor at once, and to explain what it read, could move computational oncology closer to the clinic. For patients facing the diagnostic gray zones that complicate breast cancer care today, tools that sharpen those boundaries while revealing the genes behind them are exactly the kind of advance the field has been waiting for.

Subject of Research: Interpretable multi-omics integration using hierarchical cross-attention for breast cancer subtype classification and biomarker discovery

Article Title: HCAM-BRCA: an interpretable multi-omics framework for breast cancer subtype classification and biomarker discovery

Article References: Ali, M. N., & Biswas, S. (2026). HCAM-BRCA: an interpretable multi-omics framework for breast cancer subtype classification and biomarker discovery. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06607-9

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06607-9

Keywords: breast cancer, multi-omics integration, cross-attention, machine learning, biomarker discovery, TCGA, subtype classification, PAM50, prognostic genes, precision oncology, DNA methylation, BMC Bioinformatics

The challenge that Joint-RPCA tackles is deceptively simple to state and notoriously hard to solve. Microbiome data are compositional, meaning sequencing reflects relative rather than absolute abundances. They are sparse, with many measurements containing zeros or missing values. And they span wildly different scales, because metabolomics, proteomics, and genomics generate numbers in different units and magnitudes. Traditional approaches often sidestep these problems by analyzing each data layer separately, using dimensionality reduction techniques such as principal coordinates analysis on a distance matrix. But doing so treats the data layers as independent and ignores the inherent correlations between modalities sampled from the same ecosystem, such as the production of a specific metabolite by a specific bacterium.

Joint-RPCA, developed by Bianca Cordazzo Vargas, Cameron Martino, Liat Shenhav, and colleagues spanning institutions from New York University to the University of California San Diego, the University of Turku, and Ben-Gurion University, addresses these issues head-on. The method builds on the OptSpace matrix completion framework, assuming that the input data matrices share an underlying low-rank structured component. In practice, this means the dominant biological signal, such as the difference between diseased and healthy individuals, can be captured by a small number of latent factors, even when that signal is embedded in a sea of high-rank biological and technical noise. The authors are careful to clarify that low-dimensional signal refers to the dimensionality of the latent phenotype factor, not the fraction of total variance it explains, a distinction that matters greatly in microbiome settings where disease effects may be subtle relative to interpersonal variation.

Mathematically, the workflow begins by transforming each data modality using a robust centered log-ratio transformation, which handles sparsity and compositionality without requiring imputation or pseudocounts. Then, a joint dimensionality reduction is performed via singular value decomposition optimized on a local manifold. The key architectural choice is that the sample space is estimated jointly across all modalities, while the feature space is estimated individually within each modality. This yields a shared scores matrix for subjects and distinct loadings matrices for features in each omic type. The output includes a joint low-dimensional representation of samples, feature loadings indicating each feature’s contribution to the axes of variation, and a denoised feature-feature covariance matrix that can be interpreted as a multipartite network of cross-modal interactions.

To evaluate the method, the team benchmarked it against widely used microbiome approaches, including PCoA with Bray-Curtis and Aitchison distances and the single-modality RPCA, as well as general-purpose multi-omics tools such as MOFA+, iClusterPlus, intNMF, and multiblock sPLS from mixOmics. Using data-driven simulations anchored in real data from the Integrative Human Microbiome Project, with induced sparsity ranging from 12 percent down to 3 percent observed density, Joint-RPCA consistently recovered inflammatory bowel disease-associated structure more reliably than the alternatives. Classification accuracy improved by up to sixfold in this benchmark setting, and the method showed greater Mahalanobis distances between phenotype centroids and higher PERMANOVA pseudo-F statistics across simulated densities.

Consistency of feature selection proved to be another strength. When the researchers compared the top-ranked metabolomic features identified by Joint-RPCA and MOFA+ along the component most strongly associated with IBD diagnosis, Joint-RPCA showed a 60 to 70 percent median overlap in its selections across train-test splits and sparsity levels, whereas MOFA+ exhibited less than 30 percent overlap. This indicates that Joint-RPCA more stably recovers the shared low-dimensional phenotype-associated signal rather than selecting features that fluctuate with each training set. In purely synthetic simulations with traceable signals, Joint-RPCA reliably ranked the specific features carrying induced signals among its top loadings, while competitors showed variable or inconsistent performance, particularly when signals were weak.

The method also excels at recovering biologically validated cross-modal relationships. In a study of biological soil crusts, thin living layers on arid soil surfaces, roughly 70 percent of the microbe-metabolite relationships following a wetting event had been experimentally validated, providing ground truth for benchmarking. Joint-RPCA correctly assigned positive covariance values between the cyanobacterium Microcoleus vaginatus and all metabolites the isolate was known to release, and these metabolites ranked among the top 40 co-varying molecules out of 85 total. This finding remained robust even when the sequencing data were subsampled from 50 percent dense down to 1 percent dense. Compared with correlation-based approaches and the specialized method MMvec, Joint-RPCA and MMvec both achieved significantly higher true-positive rates, precision, and recall, but Joint-RPCA did so more than 100 times faster.

That speed advantage stems from a fundamental design difference. MMvec estimates conditional probabilities between metabolite abundances and microbial reads on a per-read basis, so its runtime scales linearly with the number of sequencing reads. Joint-RPCA resolves the high-dimensionality challenge by construction and operates on a per-sample basis, so its runtime scales with the number of samples instead. In runtime experiments using the FINRISK study, one of the largest multi-omics microbiome cohorts to date with 7,167 individuals, Joint-RPCA completed analyses in minutes that would take MMvec days. When processing two independent IBD cohorts with multiple omic types, MMvec required pairwise analysis of all omic combinations, and some pairs had to be excluded because runtimes exceeded 24 hours, forcing the researchers to extrapolate. Joint-RPCA processed thousands of samples and features across omic types within seconds to minutes.

Applied to real-world data, the method delivered replicable biological findings. In the iHMP dataset, which includes matched metabolomics, proteomics, viromics, metagenomics, and metatranscriptomics from 135 samples, Joint-RPCA separated IBD from non-IBD subjects across all omic layers with a PERMANOVA pseudo-F of 17.04. It identified cross-modal markers including urobilin metabolites and Klebsiella pneumoniae that aligned with prior iHMP findings, and it succeeded where single-modality RPCA failed, using the context of proteomics, viromics, and metagenomics to reveal disease-associated patterns in metatranscriptomic and metabolomic data that were otherwise invisible. The signal replicated in an independent UCSD cohort of 146 subjects, with a significant correlation of 0.47 between the IBD-associated metagenomic feature rankings of the two cohorts, and it held in a third validation dataset combining IBD patients with 824 controls from the American Gut Project. Across all three datasets, Phocaeicola vulgatus emerged as the top bacterial species associated with IBD, consistent with its experimentally demonstrated production of disease-linked proteases.

The method’s reach extends beyond human disease. Applied to multi-omics data from human cadaver decomposition across three forensic facilities, Joint-RPCA captured the progression of accumulated degree days along its second principal component and identified a universal microbial decomposer network shared across geographically and climatically distinct sites, including fungal taxa such as Yarrowia and Candida and the bacterium Thiopseudomonas alkaliphila, which single-modality analyses missed. In mammalian gut microbiomes spanning 25 species and five omic types, Joint-RPCA amplified weak signals from gas chromatography-mass spectrometry metabolomics, improving classification of host taxonomy and digestive strategy from an AUC-ROC of 0.65 with independently ranked features to 0.88 when features were ranked in the joint context. The authors caution that the method assumes a shared low-dimensional structure across modalities, does not explicitly adjust for confounders, and does not directly model temporal dynamics, and they emphasize that their benchmark results should be read as evidence of performance in the specific scenarios studied rather than a universal ranking of integration tools. Still, with open-source implementations in Python through the gemelli package and in R through the mia Bioconductor package, plus a QIIME2 plugin and Galaxy integration, Joint-RPCA arrives as a practical, scalable tool poised to reshape how microbiome scientists read the interconnected layers of microbial ecosystems.

Subject of Research: A domain-aware multi-omics integration method for systems microbiology that jointly factorizes sparse, compositional microbiome data layers.

Article Title: Joint-RPCA: domain-aware multi-omics integration for systems microbiology

Article References: Cordazzo Vargas, B., Martino, C., Dilmore, A. H., Metcalf, J. L., Burcham, Z. M., Lahti, L., Bektanov, A., Borman, T., Salomaa, V., Niiranen, T., Havulinna, A. S., Gregor, R., Eyal, S., Meijler, M. M., Mizrahi, I., Song, S. J., Bartko, A., Dorrestein, P. C., Morton, J. T., … Shenhav, L. (2026). Joint-RPCA: domain-aware multi-omics integration for systems microbiology. Molecular Systems Biology. https://doi.org/10.1038/s44320-026-00236-3

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00236-3

Keywords: multi-omics integration, microbiome, Joint-RPCA, dimensionality reduction, matrix completion, inflammatory bowel disease, metabolomics, metagenomics, compositional data, microbe-metabolite interactions, systems microbiology, computational biology

DeepDETAILS addresses this gap by performing cross-modality deconvolution, integrating high-resolution single-cell open chromatin references with bulk sequencing data from complementary assays. This quasisupervised algorithm enables researchers to dissect locus-specific genomic signals at base-pair resolution, resolving the contributions of different cell types within heterogeneous tissue samples. Impressively, the method is compatible with various genomic layers including nascent transcription measurements from PRO-cap and PRO-seq, as well as chromatin immunoprecipitation sequencing (ChIP-seq) for histone modifications.

By leveraging single-cell chromatin accessibility as a reference, DeepDETAILS constructs precise, cell-type-resolved maps of transcriptional regulatory processes, overcoming technical barriers that have limited the study of complex tissues. In applied analyses spanning 39 human tissues and 86 cell types, the team compiled a comprehensive atlas of cell-type-specific nascent RNA synthesis and epigenetic modifications, providing an unparalleled resource for the community.

Beyond resource generation, the utility of DeepDETAILS was showcased in fine-mapping genetic risk variants associated with primary sclerosing cholangitis (PSC), a devastating liver disorder marked by progressive bile duct inflammation. The framework pinpointed specific cell types and regulatory elements implicated in disease etiology, opening new avenues for understanding pathogenic mechanisms and identifying potential therapeutic targets.

This deep-learning driven approach fundamentally transforms how bulk sequencing data can be harnessed to infer cell-type-specific regulatory activity with unprecedented resolution. It circumvents the cost and technical complexity of generating single-cell data for every assay type by computationally integrating modalities, significantly broadening the scope of genomic interrogation.

As the biomedical field continues to grapple with the complexity of cellular heterogeneity in tissues, DeepDETAILS sets a new standard for multi-omic deconvolution. Its adaptable framework promises to accelerate discovery in developmental biology, disease pathogenesis, and therapeutic intervention by providing accurate, interpretable, and scalable solutions for dissecting regulatory dynamics within diverse biological contexts.

With this tool, researchers are now equipped to unlock hidden layers of transcriptional regulation from existing bulk datasets, greatly expanding the potential for insights into the molecular architecture of human health and disease.

Subject of Research: Single-cell resolution deconvolution of bulk genomic sequencing data for transcriptional regulatory analysis

Article Title: High-resolution reconstruction of cell-type-specific transcriptional regulatory processes from bulk sequencing samples

Article References:
Yao, L., Shah, S.R., Ozer, A. et al. High-resolution reconstruction of cell-type-specific transcriptional regulatory processes from bulk sequencing samples. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03218-w

DOI: https://doi.org/10.1038/s41587-026-03218-w

The integration of spatial omics data is a complicated endeavor, primarily due to the prevalent issue of low signal-to-noise ratios—an unavoidable obstacle that traditional approaches have struggled to overcome. Addressing this challenge requires sophisticated algorithms that can effectively amalgamate disparate data types while maintaining fidelity and reliability across the different modalities being studied. In response to these pressing needs, researchers have introduced a novel deep generative model known as SWITCH (Spatially Weighted Multi-omics Integration and Cross-modal Translation with Cycle-mapping Harmonization). This innovative approach sets a new benchmark in the field of spatial multi-omics integration, combining advanced statistical methodologies with machine learning techniques.

SWITCH leverages a unique cycle-mapping mechanism that allows for the generation of reliable cross-modal translations, establishing a foundational framework that does not depend on the availability of additional paired data. This is especially advantageous in scenarios where acquiring paired datasets is logistically or financially prohibitive. The model generates what are referred to as pseudo-pairs, which act as supplementary signals to enhance the overall integration process. By utilizing computational power to create these pseudo-pairs, SWITCH effectively broadens the scope of data that can be analyzed, thereby unlocking new insights into the intricacies of biological systems.

Systematic evaluations of SWITCH reveal that it significantly outperforms existing methods in various metrics of integration accuracy. By refining the spatial domain delineation, it enables researchers to resolve brain cortical structures with an unprecedented level of detail. This capability emphasizes not only the functional efficacy of SWITCH but also its potential for transformative impacts in the fields of neuroscience and beyond. Accurate spatial representations of biological structures are crucial for understanding the underlying mechanisms of diseases, the dynamics of cellular interactions, and responses to therapeutic interventions.

The reliability of the cross-modal translations produced by SWITCH has been rigorously validated, providing researchers with a robust tool that can facilitate a range of downstream analyses. These include differential analysis, trajectory inference, and gene regulatory network inference, each critical for elucidating biological processes at both cellular and systemic levels. With such enhanced analytical capabilities, researchers are now better equipped to tackle the multi-dimensional complexities that characterize biological research today.

Additionally, the introduction of SWITCH represents a significant stride toward addressing some of the most pressing limitations faced in spatial omics research. The ability to harness unpaired data not only democratizes access to high-level analytical techniques but also accelerates scientific discovery. Researchers can now focus on developing and refining their hypotheses without being constrained by the availability of paired datasets, thereby fostering an environment of innovation and collaboration.

The implications of the SWITCH model extend well beyond basic research. It opens up new avenues for clinical applications, particularly in personalized medicine, where understanding the spatial dynamics of gene expression can tailor specific interventions for individual patients. The ability to map out complex interactions and differential expression profiles can lead to more effective diagnostics and therapeutic strategies, ultimately enhancing patient care and outcomes.

As the field of spatial omics continues to evolve, methodologies like SWITCH will be crucial in facilitating more robust integrative analyses. Researchers will likely continue to build upon the foundation laid by models such as this, pushing the envelope of what is possible in biological sciences. By incorporating machine learning into data integration processes, the potential to uncover novel biological insights grows exponentially, paving the way for breakthroughs that were previously thought unattainable.

In summary, SWITCH exemplifies a remarkable advancement in spatial multi-omics integration, offering reliable cross-modal translations that empower researchers to navigate the complexities of biological systems more effectively. The pioneering work facilitated by this model heralds a new era in computational biology—one where high-dimensional data can be synthesized into meaningful insights without the burden of extensive datasets. As researchers embark on this exciting journey, the implications for science, medicine, and beyond remain profoundly promising.

The need for reliable, integrative, and efficient tools in the field of spatial omics has never been more apparent, and SWITCH emerges as a notable solution. By embracing innovative methodologies that harness the power of modern computational techniques, the scientific community stands on the brink of potentially significant advancements that can reshape our understanding of the living world.

This breakthrough offers not just a solution to current integration challenges but also serves as a clarion call for ongoing innovation within the realms of multi-omics research. With tools like SWITCH paving the way, the pathway toward holistic biological understanding and practical clinical applications appears brighter than ever.

Through the lens of SWITCH, we are reminded of the profound impact that computational methodologies can have on biological research. As we move forward, the partnership between computational innovation and biological inquiry will undoubtedly yield new dimensions of understanding and exploration in the quest to decipher the complexities of life.

Subject of Research: Spatial multi-omics integration using computational methods.

Article Title: Integrative deep learning of spatial multi-omics with SWITCH.

Article References:

Li, Z., Qu, S., Liang, H. et al. Integrative deep learning of spatial multi-omics with SWITCH. Nat Comput Sci (2025). https://doi.org/10.1038/s43588-025-00891-w

Image Credits: AI Generated

DOI: 10.1038/s43588-025-00891-w

Keywords: Spatial omics, multi-omics integration, computational methods, deep learning, cycle-mapping, cross-modal translations, neuroscience, personalized medicine.

Dr. Poschmann’s scientific journey is as unorthodox as it is inspiring. Trained originally as a nurse, he transitioned into systems biology, a shift fueled by a passion for uncovering the stories embedded within biological data. His early fascination with genome-wide discovery, particularly in model organisms like yeast, sparked a commitment to let data guide hypothesis generation rather than constraining research within pre-set questions. This mindset has proven transformative, enabling his team to develop novel signatures of immune function that capture patient-specific trajectories through health and illness.

Central to Poschmann’s research is the concept of the circulating immune system as a living archive of past immunological events. Blood serves not merely as a diagnostic medium but as a dynamic window into the layered histories of exposure, infection, and genetic predispositions that collectively shape immune competence. By applying multi-omics profiling — integrating genomic sequences, RNA expression profiles, and protein quantifications — his lab constructs highly detailed immune circuitry maps. This approach facilitates unprecedented resolution in defining immune states, immune memory, and their fluctuations across diverse populations.

These metabolic and molecular blueprints hold transformative potential for addressing pressing clinical challenges. For example, differing immune baselines could illuminate why viral infections like SARS-CoV-2 manifest with such heterogeneous outcomes among patients. By capturing a patient’s immunological signature prior to infection or treatment, Dr. Poschmann’s team aims to predict disease severity, response to vaccines, or even likelihood of developing neuropsychiatric sequelae. This paradigm shift from reactive to predictive immunology posits a future where personalized immune profiling guides tailored interventions and proactive health strategies.

Achieving these goals requires not only biological insight but also sophisticated computational frameworks. Frustrated early in his career by the bottlenecks posed by limited bioinformatics support, Dr. Poschmann acquired programming skills independently. This technical self-reliance catalyzed a new approach to research wherein iterative data analysis, machine learning models, and systems-level integration occur fluidly within the lab. By embracing computational fluency, his group models immune complexity with high dimensionality and temporal depth — essential for decoding the stochastic yet patterned nature of immune regulation.

An emerging theme in Poschmann’s work is the profound impact of pre-existing immune conditions shaped by an individual’s life history, environment, and genetics. These foundational immune landscapes help explain individual variability in susceptibility and resilience to disease. Understanding these intrinsic immune “set points” and their molecular underpinnings represents a crucial step towards deploying immune monitoring as a routine clinical tool. Such insights may eventually inform vaccine formulation strategies optimized for subpopulations or identify early biomarkers predictive of psychiatric disorders linked to immune dysfunction.

Beyond the laboratory bench, Dr. Poschmann actively advocates for systemic improvements in research infrastructure, particularly emphasizing the need for stable career pathways for postdoctoral researchers and technical staff. He asserts that scientific advances depend heavily on continuity and collaboration, elements threatened by precarious employment conditions prevalent in academic research across Europe. Poschmann’s call to action highlights the importance of investing in the entire scientific ecosystem to sustain innovation and knowledge transfer.

At the core of his leadership is a holistic, inclusive philosophy that values originality and mindset over traditional metrics like grades. Drawing on his nursing background, he fosters a lab culture rooted in compassion, mentorship, and interdisciplinary collaboration. This ethos not only nurtures creativity but also attracts talent capable of thinking differently about complex biological problems, which is essential in navigating the multi-faceted challenges of systems immunology.

Outside the intellectual rigor of research, Poschmann finds balance in the Atlantic waves off the French coast. Surfing has become both a metaphor and practical outlet for patience, resilience, and timing — qualities mirrored in the patient, deliberate process of scientific discovery. The capricious rhythm of the ocean aligns with the uncertainty scientists embrace, where persistence eventually meets breakthrough.

Dr. Poschmann’s work exemplifies the increasingly blurred boundaries between biology, computation, and medicine. His ambition is not merely to deepen biological insights but to translate them meaningfully into clinical care. By harnessing multi-omics data and system-level analyses, he envisions a healthcare future where immune profiling informs personalized therapies, preventive measures, and real-time disease monitoring.

The implications of this research ripple far beyond immunology, touching psychiatric medicine, infectious disease management, and public health policy. The ability to quantify and interpret immune memory at scale may revolutionize how society approaches vaccination, treatment customization, and early intervention for a myriad of diseases influenced by immune dysfunction.

As the multi-omics revolution continues, several critical questions demand attention. How can complex, high-dimensional immune data be distilled into actionable clinical metrics accessible at the point of care? What infrastructural and computational frameworks must be developed to support widespread use of personalized immune profiles? And fundamentally, what societal investment and scientific collaboration will break down barriers preventing the realization of a prevention-first, precision health model?

Dr. Jeremie Poschmann’s journey and research represent a compelling microcosm of modern biomedicine’s evolution towards data-driven, integrative approaches. His pioneering multi-omic profiling of the circulating immune system not only advances scientific understanding but also lays the groundwork for a transformative impact on healthcare delivery, fostering a future where personalized medicine is the norm rather than the exception.

Subject of Research: People

Article Title: Jeremie Poschmann: Data-driven discovery in human diseases through multi-omics profiling of the circulating immune system

News Publication Date: 22-Apr-2025

Web References:
https://doi.org/10.61373/gp025k.0023
https://genomicpress.kglmeridian.com/

Image Credits: Jeremie Poschmann, PhD

Keywords: multi-omics, circulating immune system, systems biology, immunology, genomics, transcriptomics, proteomics, personalized medicine, immune profiling, data-driven discovery, SARS-CoV-2, vaccine response, psychiatric disorders